Alejandra Gonzalez-Calle

Alejandra Gonzalez-Calle

Auto-generated profile, based on publicly available information

Alejandra Gonzalez-Calle

USC Ginsburg Institute of for Biomedical Therapeutics, University of Southern California, Los Angeles, CA 90033, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 August 2020 in Ophthalmology
Verified
Journal Article
Closed access
LYLan Yue
Lan Yue
JCJohnny Castillo
Johnny Castillo
AGAlejandra Calle Gonzalez
Alejandra Calle Gonzalez
JNJay Neitz
Jay Neitz
MHMark S. Humayun
Mark S. Humayun

22 June 2023 in Cells
Verified
Journal Article
Open access
PDF file
KAKabir Ahluwalia
Kabir Ahluwalia
JMJuan-Carlos Martinez-Camarillo
Juan-Carlos Martinez-Camarillo
BTBiju B. Thomas
Biju B. Thomas
ANAditya Anil Naik
Aditya Anil Naik
AGAlejandra Gonzalez-Calle
Alejandra Gonzalez-Calle
MHMark Humayun
Mark Humayun
Retinal degenerative diseases, including age-related macular degeneration (AMD) and retinitis pigmentosa, lack effective therapies. Conventional monotherapeutic approaches fail to target the multiple affected pathways in retinal degeneration. However, the retinal pigment epithelium (RPE) secretes several neurotrophic factors addressing diverse cellular pathways, potentially preserving photoreceptors. This study explored human embryonic stem cell-derived, polarized RPE soluble factors (PRPE-SF) as a combination treatment for retinal degeneration. PRPE-SF promoted retinal progenitor cell survival, reduced oxidative stress in ARPE-19 cells, and demonstrated critical antioxidant and anti-inflammatory effects for preventing retinal degeneration in the Royal College of Surgeons (RCS) rat model. Importantly, PRPE-SF treatment preserved retinal structure and scotopic b-wave amplitudes, suggesting therapeutic potential for delaying retinal degeneration. PRPE-SF is uniquely produced using biomimetic membranes for RPE polarization and maturation, promoting a protective RPE secretome phenotype. Additionally, PRPE-SF is produced without animal serum to avoid immunogenicity in future clinical development. Lastly, PRPE-SF is a combination of neurotrophic factors, potentially ameliorating multiple dysfunctions in retinal degenerations. In conclusion, PRPE-SF offers a promising therapeutic candidate for retinal degenerative diseases, advancing the development of effective therapeutic strategies for these debilitating conditions.

1 January 2022 in BME Frontiers
Verified
Journal Article
Open access
PDF file
AGAlejandra Gonzalez-Calle
Alejandra Gonzalez-Calle
RLRunze Li
Runze Li
IAIsaac Asante
Isaac Asante
JMJuan Carlos Martinez-Camarillo
Juan Carlos Martinez-Camarillo
SLStan Louie
Stan Louie
MHMark S. Humayun
Mark S. Humayun
The purpose of this study is to develop a method for delivering antiinflammatory agents of high molecular weight (e.g., Avastin) into the posterior segment that does not require injections into the eye (i.e., intravitreal injections; IVT). Diseases affecting the posterior segment of the eye are currently treated with monthly to bimonthly intravitreal injections, which can predispose patients to severe albeit rare complications like endophthalmitis, retinal detachment, traumatic cataract, and/or increased intraocular. In this study, we show that one time moderate intensity focused ultrasound (MIFU) treatment can facilitate the penetration of large molecules across the scleral barrier, showing promising evidence that this is a viable method to deliver high molecular weight medications not invasively. To validate the efficacy of the drug delivery system, IVT injections of vascular endothelial growth factor (VEGF) were used to create an animal model of retinopathy. The creation of this model allowed us to test anti-VEGF medications and evaluate the efficacy of the treatment. In vivo testing showed that animals treated with our MIFU device improved on the retinal tortuosity and clinical dilation compared to the control group while evaluating fluorescein angiogram (FA) Images.